Loading
Life sciences · Journal article
Journal of Oncology Pharmacy Practice · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction Trastuzumab is a humanized HER2 targeting monoclonal antibody, and it is indicated for the treatment of various HER-2-positive cancers, including breast and gastrointestinal cancers. The standard protocol involves a 90-min intravenous loading dose, followed by 30-min maintenance infusions. If a maintenance dose is missed by more than a week, the prescribing information recommends a 90-min reloading infusion of 8 mg/kg, regardless of prior tolerance and duration of maintenance therapies. This study aims to assess the safety of 30-min reloading infusions which has not been previously studied. Methods This was a single-center, retrospective cohort study that compared the safety of trastuzumab reloading 8 mg/kg as 30 min infusion and 90 min infusion in adults with HER2-positive cancers at a comprehensive cancer center. The primary endpoint was the incidence of infusion-related reactions (IRRs). Secondary endpoints included IRR severity, number of symptoms, time to reaction, rate of decrease in left ventricular ejection fraction (LVEF), and IRR risk factor identification. Results A total of 169 patients were included (90-min = 123; 30-min = 46). Our findings demonstrated that the shorter 30 min infusion is as safe as 90 min infusion. The IRR rate was 0% in 30 min vs. 4% in 90 min. Additionally, the mean percentage of LVEF reduction was similar between the two cohorts (4.1% in 30 min vs. 3.97% in 90 min; P = 0.99). Conclusions Trastuzumab reloading doses can be safely administered as a 30-min infusion, without increased risk of IRR or cardiotoxicity.